To require the Food and Drug Administration to determine whether to permit the use of enriched enrollment randomized withdrawal methodology with respect to clinical trials.
About This Bill
Committee
Latest Action · September 7, 2023
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.